John J. Oppenheimer, MD, says that allergists should not be dogmatic about how they approach patient care but rather provide an individualized approach.
“If I were to summarize my 30 years in medicine, it would be defined by an evolution in our attempt to personalize care, whether we’re talking about asthma, rhinitis, urticaria or food allergy,” Oppenheimer, a clinical
Vaishanavi Kumbalwar, Senior Associate Content Writer, Allied Market Research gives an insight on how partnerships, innovations are key for therapeutic respiratory devices development
Vaishanavi Kumbalwar, Senior Associate Content Writer, Allied Market Research gives an insight on how partnerships, innovations are key for therapeutic respiratory devices development
GlaxoSmithKline Pharmaceuticals Limited launched Trelegy Ellipta (fluticasonefuroate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for ChronicObstructive Pulmonary Disease (COPD) patients in a once-daily regime.